“Looking for the very highest quality products and the consistency of a high-tech pharmaceuticals operation? Vida expects to file its licensing application before the end of April, a schedule that should allow it to have the necessary license in hand by the third quarter of this year. In the meantime, the company is raising $1.5 million at $.25 per share. That represents a market value of only $6 million for a company that now owns a 315,000-square-foot production plant with a replacement value estimated at $30 million. Personally, I think this will turn out to be an extraordinary investment. In less than a year’s time, this $.25 financing round is going to look extremely cheap.”
Related posts:
The history of the requirement that U.S. citizens use U.S. passports to travel
State Department self-censors criticism of Eritrean diaspora tax in Human Rights Report
SEC Criticizes Corporate Insiders Cashing Out Via Share Buybacks
More on the Rotten Republicans
One of the world’s largest financial services firms is mining bitcoins
Electronic car lock hack revealed after 2-year injunction by Volkswagen
Argentina’s Peso Collapses Further Despite $50 Billion IMF Bailout
Google confirms critical Android crypto flaw used in $5,700 Bitcoin heist
CA Attempt To Ban E-Cigarettes, Vaporizers Fails
Get ready for Washington’s “Automatic IRAs”
300 Year Old Russian Watch Factory Raketa Accepts Bitcoins
Fincen's New Regulations Are Choking Bitcoin Entrepreneurs
It’s all over: Bitcoin miner maker HashFast to auction remaining assets
California Senate Says No To NDAA
SmartMetric to Launch World's First Biometric Bitcoin Card